Fig. 2From: Elosulfase alfa in the treatment of mucopolysaccharidosis type IVA: insights from the first managed access agreementPatient disposition diagram. aPrevious elosulfase alfa clinical trials included NCT01415427, NCT01515956, NCT01697319, NCT00787995, NCT01242111, NCT01609062; bAs of 5th May 2020. MAA: managed access agreementBack to article page